GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (FRA:CZTA) » Definitions » 3-Year EPS without NRI Growth Rate

Checkpoint Therapeutics (FRA:CZTA) 3-Year EPS without NRI Growth Rate : 8.10% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics 3-Year EPS without NRI Growth Rate?

Checkpoint Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was €-0.21.

During the past 3 years, the average EPS without NRI Growth Rate was 8.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Checkpoint Therapeutics was 25.70% per year. The lowest was -32.10% per year. And the median was 10.25% per year.


Competitive Comparison of Checkpoint Therapeutics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Checkpoint Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's 3-Year EPS without NRI Growth Rate falls into.



Checkpoint Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Checkpoint Therapeutics  (FRA:CZTA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Checkpoint Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Checkpoint Therapeutics Headlines

No Headlines